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Abstract 
We evaluated the vasorelaxation effects of formononetin, an 
isoflavone/phytoestrogen found abundantly in Astragalus mongholicus Bunge, on rat 
isolated aorta and the underlying mechanisms involved. Cumulative administration of 
formononetin, genistein, daidzein and biochanin A relaxed 
phenylephrine-preconstricted aorta. Formononetin and biochanin A caused a similar 
magnitude of relaxation whereas daidzein was least potent. Mechanical removal of 
endothelium, L-NAME (100 µM) and methylene blue (10 µM) suppressed 
formononetin-induced relaxation. Formononetin increased endothelial nitric oxide 
synthase (eNOS), but not iNOS, activity with an up-regulation of eNOS mRNA and 
p-eNOSSer1177 protein expression. In endothelium-denuded preparations, 
formononetin-induced vasorelaxation was significantly reduced by glibenclamide (3 
µM) and iberiotoxin (100 nM), and a combination of glibenclamide (3 µM) plus 
iberiotoxin (100 nM) abolished the relaxation. In contrast, formononetin-elicited 
endothelium-independent relaxation was not altered by ICI 182,780 (10 µM, an 
estrogen receptors (ERα/ERβ) antagonist) or mifepristone (10 µM, a progesterone 
receptor antagonist). In single aortic smooth muscle cells, formononetin caused 
opening of iberiotoxin-sensitive Ca2+-activated K+ (BKCa) channels and 
glibenclamide-sensitive ATP-dependent K+ (KATP) channels. Thus, our results suggest 
that formononetin caused vascular relaxation via endothelium/NO-dependent 
mechanism and endothelium-independent mechanism which involves the activation of 
BKCa and KATP channels. 
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1. Introduction 
 
Cardiovascular disease is a major cause of death or disability in many developed 
countries. Smoking, high cholesterol and obesity are well known risk factors of 
cardiovascular disease, and they are associated with decreased availability of 
endothelial cells-derived NO in the cardiovascular system. Isoflavones are 
phytoestrogens that have been gathering an increased interest in the areas of clinical 
nutrition and diseases prevention [1,2] especially for post-menopausal women in view 
of the some unfavorable consequences/potential risks (e.g. stroke and coronary heart 
disease) associated with the use of estrogen-like substances (so-called hormone 
replacement therapy) [3]. Thus, there is an urgent need for estrogen alternatives (e.g. 
phytoestrogens) for providing beneficial cardiovascular effects. Recent studies 
provided evidence that isoflavones can restore endothelial dysfunction via an increase 
of NO generation [4–8]. 
Formononetin (7-hydroxy-3(4-methoxypheny)chromone (C16H12O4) (Fig. 1)) is a 
isoflavonoid found abundantly in Traditional Chinese Medicine Astragalus 
mongholicus Bunge (known as Huang Qi in China and Ougi in Japan) and Trifolium 
pratense L (red clover) which belongs to the family Leguminosae. The extract of 
these herbs has been used clinically to treat different diseases including 
cardiovascular diseases in China for a long time [9–11]. In addition, formononetin 
possesses hypolipidemic properties [12], mammary gland proliferation function [13], 
anti-oxidative and estrogenic effects [14]. The extract of Astragalus membraneaceus 
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has also been demonstrated to possess endothelium-dependent and -independent 
vasodilatory effects [15–17] and daidzein, a metabolite of formononetin formed in 
vivo, can relax rats’ aorta and pulmonary artery [18–20]. However, the underlying 
mechanisms of formononetin involved (especially its effects on ion channels 
modulation) in eliciting vasorelaxation has not been elucidated in details. Thus, in this 
study, we tested the hypothesis that formononetin-induced vascular relaxation 
involved the openings of K+ channels of the vascular smooth muscle. More 
importantly, as formononetin is a phytoestrogen which shares a chemical structure 
similar to estrogen/progesterone (Fig. 1), the participation of estrogen and 
progesterone receptors in mediating the vascular responses will be elucidated. 
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2. Materials and methods 
 
2.1. Drugs and chemicals 
 
Formononetin was purchased from Acros Organics (Belgium) and the stock 
solution (100 mM) of formononetin was prepared in dimethyl sulphoxide and stored 
at -20 °C until use. Genistein, daidzein, biochanin A, phenylephrine hydrochloride, 
acetylcholine hydrochloride (ACh), neostigmine hydrobromide, indomethacin, 
Nω-nitro-L-arginine methyl ester (L-NAME), methylene blue (MB), proporanolol and 
prazosin were obtained from Sigma-Aldrich (USA). 1400W, ICI 182,780, 
mifepristone, iberiotoxin and glibenclamide were purchased from Tocris Bioscience 
(UK). Kits for the determination of nitric oxide (NO) levels, endothelial NO synthase 
(eNOS), inducible NOS (iNOS) were provided by Nanjing Jiancheng Bioengineering 
Company (PR China). Other chemicals used were analytical grade. 
 
2.2. Arterial rings preparation 
 
Male Sprague-Dawley rats (~250-300 g) were killed by cervical dislocation, and 
thoracic aortas were dissected from animals immediately. The thoracic aortas were 
cleared from connective tissues and cut into rings (3 mm in length) and immersed in 
Krebs’ solution of the following composition (mM): NaCl 118, KCl 4.7, MgSO4 1.2, 
KH2PO4 1.2, NaHCO3 25, glucose 11 and CaCl2 1.8 (pH 7.4). Care was taken not to 
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touch the lumen of the thoracic aortas during dissection to ensure the endothelium 
intact, unless otherwise stated. The thoracic aortic rings were immersed in a 5 mL 
glass (water-jacketed) tissue baths containing Krebs’ solution (37 ± 1 °C) aerated 
continuously with a gas mixture of 95% O2 and 5% CO2 (pH 7.4; 37 ± 1 °C). The 
thoracic aortic rings were mounted on L-shaped metal prongs, which were connected 
to a force displacement MLT1030/D transducer (AD Instruments, Australia) coupled 
to the data acquisition programme (PowerLab 8SP, AD Instruments, Australia) for 
continuous recording of isometric tension changes. An optimal load of 10 ± 1 mN 
(determined from our preliminary studies) was applied progressively (2 mN per min) 
to aortic rings. Then, tissues were allowed to equilibrate for 60 min under the optimal 
resting tension. During the equilibration period, tissues were washed with drug-free 
Krebs’ solution every 15 min and the resting tension was readjusted, if necessary, 
before commencing the experiments. After equilibration, the integrity of the aortic 
rings was confirmed with high K+ (65 mM) until two consecutive contractile 
responses were reproducible. To exclude the involvement of cyclo-oxygenase cascade, 
indomethacin (1 µM, a non-selective cyclo-oxygenase inhibitor) was included in the 
bath solution throughout the experiments. After equilibration, the aortic ring was 
challenged with phenylephrine (1 µM) to establish a sustained contraction (~20 mN) 
before fomononetin and other drugs (genistein, diadzein and biochanin A) (0.1 µM - 
100 µM) were added cumulatively to the organ baths. A completed (i.e. 100 %) 
relaxation was considered when the phenylephrine-induced active tone returned to 
basal level. 
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The integrity of the functional endothelium was confirmed by acetylcholine (10 
µM)-induced relaxation (> 85%) on high K+ (30 mM) pre-constricted aortic 
preparations. In some studies, the successful removal of endothelium (by mechanical 
rubbing the lumen of the aorta with a blunted forceps) was considered when the 
acetylcholine (10 µM)-induced relaxation was < 5%. In studies with manoeuvres such 
as endothelium denudation and administration of L-NAME, concentration of 
phenylephrine added was adjusted (0.35 - 0.6 µM) so as to achieve a comparable 
magnitude of contractile tone (~20 mN) as observed in endothelium-intact 
preparations in response to 1 µM phenylephrine challenge. Inhibitors employed in this 
study were added 30 min before phenylephrine administration and present throughout 
the experiments. 
The Animal Experimentation Ethics Committee of The Chinese University of 
Hong Kong (HKSAR, PR of China) approved all experiments performed in this study 
(approval no: 04/054/MIS). The recommendations from the Declaration of Helsinki 
and the internationally accepted principles for the use of experimental animals were 
adhered to. Every effort was made to limit animal suffering and to limit the number of 
animals used in these experiments. 
 
2.3. Incubation of aortic rings 
 
To evaluate the in vitro effect of formononetin on isolated aorta, the aortas 
(thoracic and abdominal) were excised and cleared of all adherent tissues in ice-cold 
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phosphate buffered saline (pH 7.4) under sterile conditions. The isolated aortas were 
placed in ice-cold Krebs’ solution, washed three times in phosphate buffered saline, 
and cut into segments of 1 cm long using a scalpel. Four aortic rings were obtained 
from each rat. The aortic rings were incubated in 24-well plate with physiological salt 
solution (2 ml per well) in the presence of 1 µM acetylcholine (plus 1 µM 
neostigmine, an anti-cholinesterase), formononetin (10 µM, 100 µM and 1 mM) or 
saline (served as control) under an atmosphere of 5% CO2 and 95% O2 at 37 °C. After 
2 hr incubation, each segment was blotted dry and weighed, and immediately stored at 
-80 °C for NOS activity assay or in liquid nitrogen for RNA and protein extraction. 
 
2.4. NO content in culture medium and NOS activity of aortic rings 
 
After 2 hr incubation, the medium (2 ml) of each well was collected in 
micro-centrifuge tubes, and dried by vacuum freeze-drying. The pellets collected were 
re-dissolved in distilled water (300 µl). Nitric oxide content present in the medium 
was determined according to the Griess methods [21], and nitrite concentrations were 
determined at 550 nm using the standard solutions of sodium nitrite. 
The NOS activity of isolated aorta was measured as described previously [22]. 
The frozen sample of aorta (weight = 0.03 – 0.04 g) was homogenized in ice-cold 
saline (final concentration 10% (w/v)) and centrifuged (3000 rpm, 10 min). The 
supernatant collected was used for the determinations of total NOS (tNOS) and 
inducible NOS (iNOS) activities using kits following the instructions of manufactory. 
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The protein content was evaluated according to Bradford methods. Endothelial NOS 
(eNOS) activity was estimated (to measure the color change of reagent at 530 nm) as 
the difference between tNOS and iNOS. It is based on the fact that eNOS is a 
Ca2+-dependent isoform whereas iNOS is a Ca2+-independent isoform. Thus, the 
activity of iNOS was estimated in the presence of eNOS inhibitor (L-NAME) plus 
EGTA (2 mM, a Ca2+ chelator) [22]. The NOS activities measured were expressed in 
U/mg protein. 
 
2.5. Isolation and Quantification of mRNA 
 
To determine the gene expression levels, total RNA was isolated from aorta using 
TRIzol reagent (Molecular Research Center, Inc., USA). The RevertAid 1st Strand 
cDNA synthesis system for RT-PCR (MBI Fermentas) with oligo(dT)18 was used to 
obtain the cDNA (in 20 µl of RT-reaction mixture). Total reaction mixture (20 µl) 
containing 3 µl of the RT-reaction mixture and 0.2 µM of each primer set (Table 1) 
was prepared to determine eNOS mRNA expression using real time RT-PCR 
procedures [ABI PRISM 7000 Sequence Detection System with qPCR SuperMix kit 
(Invitrogen)]. Expression levels of cDNA were compared to internal standard 
glyceraldehydes 3-phosphate dehydrogenase (GAPDH), a housekeeping gene, to 
correct for differences in the RNA quantity of samples used. The real-time PCR 
reaction procedures are as follows: 50 °C for 2 min (UDG incubation), 95 °C for 10 
min (UDG inactivation and DNA polymerase activation), then 40 PCR cycles which 
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consisted of denaturation for 15 s at 95 °C, annealing and extension for 60 s at 53 °C. 
The second derivative maximum (log linear phase) for each amplification curve was 
determined using the GAPDH standard curve to calculate the amount of product 
generated. Each real-time RT-PCR reaction was performed in triplicate. The 
expression levels of mRNA were expressed as the ratios of mRNA expression of NOS 
enzyme to that of GAPDH. 
 
2.6. Western immunoblot analysis of phospho—eNOS and eNOS protein expression on 
thoracic aortas 
 
To determine the protein expression levels, thoracic aortas from different 
treatment groups were homogenized in the presence of protease inhibitors to obtain 
extracts of proteins. Protein concentrations were determined using BCA protein 
assay kit (Pierce, USA). Samples (25 µg of protein per lane) were loaded onto a 10% 
SDS-polyacrylamide electrophoresis gel. After electrophoresis (180V, 60 min), the 
separated proteins were transferred (12 mA, 45 min) to polyvinylidene difluoride 
membrane (PerkinElmer Life Sciences, USA). Non-specific sites were blocked with 
5% non-fat dry milk for 120 min, and the blots were then incubated with anti- 
phospho-eNOSSer1177 antibody (Upstate, USA) overnight at 4 °C. Anti-rabbit 
HRP-conjugated IgG, 1:1,000 (Bio-Rad, USA) was used to detect the binding of its 
correspondent antibody. Membranes were stripped and re-blotted with anti-eNOS 
antibody, 1:10,000 (Sigma-Aldrich, USA) to verify an equal loading of protein in 
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each lane. The protein expression was detected with Western Lightning 
Chemiluminescence Reagent Plus (PerkinElmer Life Sciences, USA) and quantified 
using Scion Image (version 1.64) programme (NIH, USA). 
 
2.7. Isolation of aortic smooth muscle cells and patch-clamp electrophysiology 
 
Rat aorta (endothelium denuded) smooth muscle cells were enzymatically 
dissociated (using collagenase and papain) with methods as reported previously by 
our group [23–25] for single cell patch-clamp electrophysiology experiments. 
Solutions (external bathing solutions and pipette solutions) and voltage protocols used 
for whole-cell recordings of BKCa and KATP channels were similar to our previous 
reports [24,25].  
 
2.8. Statistical analysis 
 
Data are expressed as means ± S.E.M., and n denotes the number of replications 
for each data point. Relaxation was expressed as the percentage of the contraction 
elicited by phenylephrine. GraphPad Prism 4.02 (San Diego, California, USA) was 
used to fit sigmoidal curves and to determine the maximum relaxation effect. After 
validation of each parameter for homogeneity of variance, differences between groups 
were assessed by one-way analysis of variance (ANOVA) using SPSS (Version 15) 
software package for Windows (Chicago, IL, USA). Post hoc testing was performed 
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for inter-group comparisons using the least significance difference (LSD) test. 
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3. Results 
 
3.1. Relaxation of rat aorta by formononetin 
 
After the phenylephrine (1 µM)-induced contraction reached a 
sustained/steady-state condition, cumulative application of formononetin (0.1 - 100 
µM) caused a concentration-dependent relaxation and a maximum relaxation of 98.50 
± 1.50 % was observed in endothelium-intact preparation. Other phytoestrogens 
(genistein, daidzein and biochanin A) were evaluated and compared. Similar to 
formononetin, cumulative administration of these compounds caused a 
concentration-dependant relaxation of phenylephrine-preconstricted aorta (n = 5 - 6) 
(Fig. 2). Genistein (≤ 10 µM) elicited a smaller magnitude of relaxation compared to 
formononetin whereas biochanin A (> 1 µM) induced a similar degree of relaxation as 
produced by formononetin (Fig. 2). In contrast, daidzein was the least potent one in 
causing aortic relaxation (Fig. 2). L-NAME (100 µM, a common eNOS inhibitor) and 
methylene blue (10 µM, an inhibitor of guanylate cyclase), but not 1400W (1 μM, a 
selective iNOS inhibitor) or propranolol (1 μM, a non-selective β-adrenoceptor 
blocker), markedly suppressed formononetin-induced relaxation in endothelium-intact 
preparations (Fig. 3A). 
In endothelium-denuded preparations, formononetin (over the same 
concentration range) elicited a lesser degree of relaxation and a maximum relaxation 
of 53.28 ± 3.70 % was observed (n = 5 - 6) (Fig. 3B). Methylene blue (10 µM) 
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attenuated, but not abolished, formononetin-elicited relaxation in 
endothelium-denuded preparations (n = 5 - 6) (Fig. 3B). However, ICI 182,780 (10 
µM, an estrogen receptor antagonist), mifepristone (10 µM, a progesterone receptor 
antagonist) and propranolol (1 µM, a non-selective β-adrenoceptor antagonist) failed 
to alter formononetin-induced relaxation observed in both endothelium-intact and 
-denuded preparations (n = 5 - 6) (data not shown). In time-matched controls, there 
was no apparent change in phenylephrine-induced active tone of both 
endothelium-intact and -denuded preparations (data not shown). In 
endothelium-denuded preparations under resting tension, cumulative application of 
phenylephrine (10 nM - 10 µM) caused a concentration-dependent contraction and 
prazosin (10 µM, an α1-adrenoceptor blocker), but not formononetin (0.01, 0.1 and 1 
mM), suppressed phenylephrine-induced contraction (n = 5 - 6) (data not shown). 
 
3.2. Role of K+ channels activation in formononetin-induced relaxation of 
endothelium-denuded preparations 
 
In endothelium-denuded preparations, glibenclamide (3 µM, an ATP-sensitive K+ 
(KATP) channel blocker) markedly suppressed formononetin-mediated relaxation (n = 
5) (Fig. 4A). A higher concentration of glibenclamide (10 µM) was examined but the 
phenylephrine-induced active tone was not sustained (n = 6) (data not shown). Thus, 
effects of glibenclamide (10 µM) on formononetin-elicited relaxation could not be 
determined accurately. Similar to glibenclamide, iberiotoxin (100 nM, a potent and 
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highly selective Ca2+-activated K+ (BKCa) channel blocker) markedly reduced the 
magnitude of formononetin-induced relaxation in endothelium-denuded preparations 
(n = 5) (Fig. 4B). A combination of glibenclamide (3 µM) plus iberiotoxin (100 nM) 
completely abolished formononetin-induced relaxation in endothelium-denuded 
preparations (n = 5) (Fig. 4C). Application of glibenclamide, iberiotoxin and a 
combination of glibenclamide plus iberiotoxin did not alter the resting tension of the 
preparations (n = 5 - 6) (data not shown). 
In single aortic smooth muscle cells, formononetin (10 µM and 100 µM) 
activated, in a concentration-dependent manner, the basal KATP channel openings (n = 
6) (Fig. 5A) which was eradicated by glibenclamide (3 µM) (n = 6) (Fig. 5A). In 
addition, formononetin (10 µM, 100 µM and 1 mM) activated, in a 
concentration-dependent manner, the basal BKCa channels (n = 6) (Fig. 5B) which 
was sensitive to iberiotoxin (100 nM) (n = 6) (Fig. 5B). 
 
3.4. Determination of nitric oxide production 
 
To further investigate the effects of formononetin on NO release from aortic 
endothelial cells, isolated aortic rings were treated with different concentrations of 
formononetin, and acetylcholine (1 µM) was used as the reference for comparison. 
Before the addition of acetylcholine, no detectable levels of NO could be measured 
even after 2-hr incubation. Immediately after acetylcholine (1 µM) (with neostigmine 
(10 µM, an inhibitor of cholinesterase [26])) was added, NO production was increased 
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and it reached 88.8 ± 6.44 µM NO per g of aortic ring (Control in Fig. 6) at the end of 
the incubation period. Similar to acetylcholine, formononetin (10 µM, 100 µM and 1 
mM) caused a significant and concentration-dependant increase in NO release. The 
increase in NO production caused by formononetin (10 µM, 100 µM and 1 mM) were 
higher than that by acetylcholine (1 µM) by 2.5 % (P > 0.05), 14.5 % (P < 0.05) and 
17.2 % (P < 0.001), respectively (n = 4) (Fig. 6). 
 
3.5. Determination of NOS activity 
 
Formononetin (10 µM, 100 µM and 1 mM) markedly increased NOS 
(presumably eNOS) activity by 31.5% (3.56 ± 0.41 U/mg protein, P > 0.05), 65.6% 
(4.49 ± 0.34 U/mg protein, P < 0.05) and 70.8% (4.63 ± 1.28 U/mg protein, P < 0.05), 
respectively (n = 5) (Fig. 7). In the absence of [Ca2+]o (presumably representing iNOS 
activity), formononetin has no measurable effects on NOS activity (n = 5) (Fig. 7). 
 
3.6. Determination of eNOS mRNA and protein expression 
 
Formononetin (10 µM, 100 µM and 1 mM) up-regulated eNOS mRNA 
expression, and a significant increase of eNOS mRNA expression of 1.26 ± 0.17 
(92.5 %) and 1.60 ± 0.27 (142.9 %) was observed in the presence of 100 µM and 1 
mM formononetin, respectively (n = 5) (Fig. 8A). In addition, formononetin (10 µM, 
100 µM and 1 mM) caused a concentration-dependent enhancement of 
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phospho-eNOSSer1177 protein expression with no apparent change in total eNOS 
expression (n = 5) (Fig. 8B). 
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4. Discussion 
 
The present study demonstrates, for the first time, that formononetin (a 
phytoestrogen) elicited a concentration-dependent relaxation of rat pre-contracted 
thoracic aortic rings through both endothelium-dependent and -independent 
mechanisms. Our results (using pharmacological/chemical and molecular biology 
approaches) illustrate that the endothelium-dependent component of 
formononetin-induced relaxation, similar to other NO/endothelium-related 
vasorelaxants, is associated with an increase in NO release which is due to an 
enhanced eNOS mRNA expression, protein expression of p-eNOSSer1177 
(phosphorylated/activated form of eNOS) as well as an increase of eNOS activity. 
However, our results revealed that acetylcholine managed to cause “a comparable 
magnitude” of NO release at a much lower concentration (i.e. 1 µM). These results 
therefore suggest that despite the fact that formononetin caused NO generation from 
endothelial cells of rat aorta, it is less potent than acetylcholine. 
Other phytoestrogens tested in this study (genistein, daidzein and biochanin A) 
which shared a similar chemical structure to formononetin also elicited a 
concentration-dependent relaxation of endothelium-intact aorta with a “similar” 
relaxation profile. It is important to point out that daidzein (a metabolite of 
formononetin formed in vivo) was ~10-fold less potent than formononetin in 
producing relaxation. The discrepancy in relaxation responses of formononetin and 
daidzein observed in this study is unknown. It is tempting to speculate that 
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consumption of herbs e.g. red clove and Astragalus mongholicus Bunge which 
contain a high content of formononetin [27,28] may provide greater beneficial effects 
(e.g. vasorelaxation) to the cardiovascular systems. 
The presence of L-NAME (a common eNOS inhibitor) and methylene blue (a 
guanylate cyclase inhibitor) mimicked the effects of mechanical removal of 
endothelium, and an attenuation of relaxation caused by formononetin was observed. 
In fact, a careful examination of the concentration-response curves of formononetin 
revealed that methylene blue (10 µM) caused a greater degree of reduction, compared 
to L-NAME, of formononetin-induced relaxation of endothelium-intact preparations 
(will be discussed below). Nonetheless, our results clearly demonstrate that 
formononetin caused a NO-/endothelium-/guanylate cyclase-dependent relaxation. 
The possible involvement of other NOS isoform such as the inducible NOS (iNOS) 
was considered. However, our results illustrate that iNOS probably plays no role in 
the enhanced NO release upon the challenge of formononetin as there was no mRNA 
and protein expression of iNOS could be detected in our preparations in response to 
formononetin and acetylcholine challenge (data not shown). In addition, no significant 
change in NOS activity caused by formononetin was detected in the absence of 
[Ca2+]o. Thus, our results suggest that the Ca2+-dependent NOS isoform (i.e. eNOS) 
but not the Ca2+-independent isoform (i.e. iNOS) is responsible for 
formononetin-induced NO release from endothelial cells. In line with these 
observations, 1400W (a highly selective iNOS inhibitor) [29] failed to alter 
formononetin-induced endothelium-dependent relaxation. 
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In addition to the involvement of NO/eNOS cascade of endothelial cells, the 
relaxation response of formononetin reduced after the removal of the influence of 
NO/endothelium (although the magnitude of relaxation was smaller compared to that 
observed in endothelium-intact preparations) suggesting that formononetin caused an 
endothelium-independent relaxation. As mentioned above, methylene blue (a soluble 
guanylate cyclase inhibitor), glibenclamide (a KATP channel inhibitor) and iberiotoxin 
(a potent BKCa channel blocker), but not L-NAME, attenuated formononetin-induced 
relaxation of endothelium-denuded preparations. Interestingly, a combination of 
glibenclamide and iberiotoxin abolished formononetin-elicited 
endothelium-independent relaxation. Thus, our results demonstrate that the 
endothelium-independent component of formononetin-induced relaxation involved 
the activation of guanylate cyclase as well as the opening of KATP and BKCa channels. 
To strengthen our conclusion on the type(s) of ion channels involved in 
formononetin-induced endothelium-independent relaxation, BKCa and KATP channels 
gatings of single cells of aorta were measured. Our novel results reveal that 
formononetin activated glibenclamide-sensitive KATP and iberiotoxin-sensitive BKCa 
channels which are responsible for the endothelium-independent component of 
formononetin-induced relaxation. 
As illustrated in Fig. 1, formononetin is a phytoestrogen but the failure of ICI 
182,780 (10 µM, an estrogen receptors (ERα/ERβ) antagonist) and mifepristone (10 
µM, a progesterone receptor antagonist) in altering formononetin-induced 
vasorelaxation argued against the contribution of estrogen receptor and progesterone 
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receptor activation. The possible participation of α and β-adrenoceptors on 
formononetin-induced aortic relaxation was considered. Our results however suggest 
that neither α1- nor β2-adrenoceptors were involved as the presence of prazosin and 
propranolol did not modify phenylephrine-induced contraction and 
formononetin-evoked relaxation, respectively. 
In conclusion, our novel results demonstrate, for the first time, that formononetin 
(a phytoestrogen) possesses endothelium-/NO-dependent and 
endothelium-independent relaxation effects. The endothelium-independent component 
of formononetin-induced relaxation is associated with the activation of both KATP and 
BKCa channels of the vascular tissues. Thus, our results suggest that consumption of 
herbs containing formononetin (which is devoid of estrogen/progesterone receptors 
activation) may provide beneficial effects to the cardiovascular systems of 
postmenopausal women. 
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Figure legends 
 
 
Fig. 1. Chemical structures of formononetin, genistein, daidzein, biochanin A, 
estrogen and progesterone. 
 
Fig. 2. Cumulative concentration-response curves of formononetin (○), genistein (▼), 
daidzein () and biochanin A (◆) in phenylephrine (1 µM) pre-contracted rat 
isolated thoracic aorta (endothelium intact). Data are expressed as means ± S.E.M. (n 
= 5 - 6). 
 
Fig. 3. (A). Effects of L-NAME (100 µM, ▲), methylene blue (10 µM, ▼), W1400 
(1 µM, ◆) and propranolol (1 µM,●) on formononetin-induced relaxation (control, 
○) of phenylephrine pre-contracted rat isolated aorta (endothelium intact). (B) Effects 
of methylene blue (10 µM, ▲) on formononetin-induced relaxation (control, ○) of 
phenylephrine pre-contacted rat isolated aorta (endothelium denuded) (-Endo). Data 
are expressed as means ± S.E.M. (n = 5 - 6). 
 
Fig. 4. Effects of (A) glibenclamide (3 µM, ●), (B) iberiotoxin (100 nM, ▲) and (C) 
a combination of glibenclamide (3 µM) plus iberiotoxin (100 nM) (▼) on 
formononetin-induced relaxation (control, ○) of phenylephrine pre-contracted rat 
isolated aorta (endothelium denuded). Data are expressed as means ± S.E.M. (n = 5 - 
6). *P < 0.05, **P < 0.01 and ***P < 0.001 compared to controls (○). 
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Fig. 5. Effects of formononetin on (A) KATP channels and (B) BKCa channels of rat 
aortic smooth muscle cells. (A) Insets show representative whole-cell KATP channels 
elicited with test potentials of -100mV to +40mV (a 20-mV increment for a 600-ms 
duration, 0.1 Hz) from a holding potential of -60 mV. Calibration bars: 100 pA and 
250 ms. Pipette solution contained 100 nM ATP. Summary of the effects of 
glibencalmide (3 µM), formononetin (10 µM and 100 µM) (with and without 
glibenclamide 3 µM) on the current-voltage relationship of the whole-cell KATP 
channels of rat aortic smooth muscle cells. (B) Insets show representative whole-cell 
BKCa channels elicited with test potentials of -80mV to +80mV (a 20-mV increment 
for a 500-ms duration, 0.1 Hz) from a holding potential of -60 mV. Calibration bars: 
400 pA and 250 ms. Pipette solution contained ~400 nM Ca2+. Summary of the effects 
of iberiotoxin (100 nM), formononetin (10 µM, 100 µM and 1 mM) (with and without 
iberiotoxin 100 nM) on the current-voltage relationship of the whole-cell BKCa 
channels of rat aortic smooth muscle cells. Data are expressed as means ± S.E.M. (n = 
6). *P < 0.05 versus control. 
 
Fig. 6. Determination of nitric oxide (NO) production (µM/g of aorta), in vitro, from 
rat isolated aortas (endothelium intact) in response to acetylcholine (ACh, 1 µM) and 
formononetin (10 µM, 100 µM, 1 mM). Data are expressed as means ± S.E.M. (n = 4). 
*P < 0.05 and ***P < 0.001 versus ACh. 
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Fig. 7. Determination of eNOS and iNOS activities of rat isolated aorta (endothelium 
intact) in response to formononetin (10 µM, 100 µM, 1 mM). Data are expressed as 
means ± S.E.M. (n = 5). *P < 0.05 versus control. 
 
Fig. 8. (A). Effects of formononetin (10 µM, 100 µM, 1 mM) on eNOS mRNA 
expression (eNOS mRNA/GADPH) of rat isolated aorta (endothelium intact) 
determined by real time PCR analysis. Data are expressed as means ± S.E.M. (n = 5). 
*P < 0.05 and **P < 0.01 versus control (B) Effects of formononetin (10 µM, 100 
µM, 1 mM) on phospho-eNOSSer 1177 protein and total eNOS protein expression of rat 
isolated aorta (endothelium intact). Data are expressed as means ± S.E.M. (n = 5). *P 
< 0.05, **P < 0.01 and ***P < 0.001 versus control. 
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Table 1 
The primer sequences used for real time RT-PCR experiments 
 
  
Gene name Forward primer    Reverse primer Product size (bp) Accession Number 
eNOS 5’GGATTCTGGCAAGACCGATTAC3’ 5’GGTGAGGACTTGTCCAAACACT3’ 159 U18336 
GAPDH 5’TGCACCACCAACTGCTTAG3’ 5’AGTGGATGCAGGGATGATGT3’ 180 NM017008 
 
 
 33 
 
 
 
 
 
 
OOH
O
OCH3
OOH
OH O
OH
OOH
O
OH
OOH
OH O
OCH3
OH
CH3 OH
O
CH3
CH3 CH3
O
Formononetin Genistein
Daidzein Biochanin A
Estrogen Progesterone
Fig. 1 
 34 
 
 
 
 
 
 
 
 
 
 
-7.0 -6.5 -6.0 -5.5 -5.0 -4.5 -4.0
0
20
40
60
80
100
Daidzein
Formononetin
Genistein
Biochanin A
log [Drug] (M)
R
el
ax
at
io
n 
(%
)
Fig. 2 
 35 
 
 
 
Fig. 3 
-7.0 -6.5 -6.0 -5.5 -5.0 -4.5 -4.0
0
20
40
60
80
100
Control
L-NAME
Methylene Blue
1400W
Propranolol
log [Formononetin] (M)
R
el
ax
at
io
n 
(%
)
-7.0 -6.5 -6.0 -5.5 -5.0 -4.5 -4.0
0
20
40
60
80
100
Control (- Endo)
Methylene Blue (- Endo)
log [Formononetin] (M)
R
el
ax
at
io
n 
(%
)
 36 
 
Fig. 4 
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Fig. 5
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Fig. 8
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